FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 64967

News▲ Bullish

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-05 11:50 UTC
LAST UPDATE2026-10-05 11:50 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Additional dermatology data supports label expansion and prescribing momentum for Lilly's atopic dermatitis drug.

Lilly builds clinical case for skin drug franchise
CATALYST TO WATCH

Conference data readouts and physician uptake

MAIN RISK

Data may not shift prescribing practice

FULL DISPATCH

Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis Exploratory biomarker analysis provides deeper insights on the immunometabolic biology of...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-05 11:50 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.